5 Fc Engineered Antibodies and its Role in Antibody Function

The Fc and Glycoengineered Antibodies Market is gaining significant attention due to advancements in antibody engineering, which are transforming therapeutic landscapes. Fc engineering, a pivotal aspect of antibody development, involves modifying the Fc (fragment crystallizable) region of antibodies to enhance their therapeutic efficacy, safety, and pharmacokinetics. We analyzed over 170 Fc engineered and glycoengineered antibodies that are developed / are being developed to treat various types of disease indications. In this article, discover five Fc engineered antibodies and their role in antibody function.

Fc engineered antibodies are specifically designed to optimize the interaction between the Fc region of an antibody and various Fc receptors or complement proteins. These modifications can significantly enhance the antibody's effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and prolongation of serum half-life. The Fc and Glycoengineered Antibodies Market has witnessed remarkable growth due to these advancements, contributing to the development of more effective biologics.

Roots Analysis has conducted an exhaustive study on Fc Engineered and Glycoengineered Antibodies Market featuring the current market landscape and future opportunity for the Fc engineered and glycoengineered antibodies, over a span of 11 years.

Table of Contents

Below, we have listed (in alphabetical order), the five Fc engineered and glycoengineered antibodies in the antibody industry.

1. Atezolizumab
2. Daratumumab
3. Emapalumab
4. Mogamulizumab
5. Obinutuzumab

Interested in exploring all 170+ Fc engineered and Glycoengineered Antibodies and their role in antibody function?

Discover Below the Details on 5 Fc Engineered Antibodies

Let us deep dive to understand the activity of the 5 Fc engineered antibodies in the Antibody market. It is essential to note that the selection of top antibodies can differ substantially according to the defined criteria.

1. Atezolizumab (Tecentriq)

Atezolizumab, an anti-PD-L1 monoclonal antibody, features an engineered Fc region that reduces its interaction with Fcγ receptors. This modification minimizes the risk of ADCC against immune cells expressing PD-L1, thereby enhancing its safety profile. The success of atezolizumab in cancer immunotherapy highlights the potential of Fc engineering in expanding therapeutic indications, influencing the Fc and Glycoengineered Antibodies Market Size.

Atezolizumab: Overview

Parameters	Details
Drug Developer Logo
Year of Approval (US)	May 2016
Indications	Non-Small Cell Lung Cancer , Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Alveolar Soft Part Sarcoma
Revenues 2023 ($ Million)	4,3491

In August 2023, subcutaneous formulation of Tecentriq received approval in the EU. The SC Tecentriq saves time for drug administration compared to the IV infusion route.

Further details on recent developments related to the Fc engineered antibodies have been provided in detail in the report.

2. Daratumumab (Darzalex)

Daratumumab, a glycoengineered anti-CD38 antibody, has been optimized to enhance its binding to FcγR receptors, thereby increasing ADCC and CDC activities. This enhancement has proven beneficial in the treatment of multiple myeloma, setting a benchmark in Fc engineering and contributing to the growth of the Fc and Glycoengineered Antibodies Market.

Daratumumab: Overview

Parameters	Details
Drug Developer Logo
Year of Approval (US)	November 2015
Indications	Multiple Myeloma
Revenues 2023 ($ Million)	9,7442

In August 2024, subcutaneous Darzalex received approval for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma, in combination with bortezomib, lenalidomide, and dexamethasone.

Further details on recent developments related to the Fc engineered antibodies have been provided in detail in the report.
 

3. Emapalumab (Gamifant)

Emapalumab is a fully human anti-interferon gamma antibody that has been Fc-engineered to improve its therapeutic efficacy. It is used in the treatment of primary hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening condition. The development and success of emapalumab underscores the importance of Fc engineering in addressing unmet medical needs, propelling the Fc and Glycoengineered Antibodies Market Growth.

Emapalumab: Overview

Parameters	Details
Drug Developer Logo
Year of Approval (US)	November 2018
Indications	Hemophagocytic Lympho-Histiocytosis
Revenues 2023 ($ Million)	2763

In May 2024, the company received fast track designation for use of Emapalumab to treat Macrophage Activation Syndrome (MAS); the drug is currently in phase III for this indication.

Further details on recent developments related to the Fc engineered antibodies have been provided in detail in the report.

4. Mogamulizumab (Poteligeo)

Mogamulizumab, an anti-CCR4 monoclonal antibody, is another example of successful Fc engineering. Its Fc region has been modified to enhance ADCC against CCR4-expressing cells. This antibody has shown efficacy in treating certain types of T-cell lymphomas, further driving the expansion of the Fc and Glycoengineered Antibodies Market Share.

Mogamulizumab: Overview

Parameters	Details
Drug Developer Logo
Year of Approval (US)	August 2018
Indications	Mycosis Fungoides
Revenues 2023 ($ Million)	2104

Further details on recent developments related to the Fc engineered antibodies have been provided in detail in the report.

5. Obinutuzumab (Gazyva)

Obinutuzumab, a glycoengineered anti-CD20 monoclonal antibody, exemplifies the impact of Fc engineering. Its Fc region has been modified to increase affinity for FcγRIIIa receptors, enhancing ADCC activity. Obinutuzumab has shown improved efficacy in treating B-cell malignancies compared to earlier anti-CD20 antibodies like rituximab, marking a significant advancement in the Fc and Glycoengineered Antibodies Market.

Obinutuzumab: Overview

Parameters	Details
Drug Developer Logo
Year of Approval (US)	November 2013
Indications	Chronic Lymphocytic Leukemia, Follicular Lymphoma
Revenues 2023 ($ Million)	9351

Further details on recent developments related to the Fc engineered antibodies have been provided in detail in the report.

What About the Other Fc Engineered and Glycoengineered Antibodies?

The above presentation features five Fc engineered Antibodies selected from a pool of over 170 drugs that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources

1. https://assets.roche.com/f/176343/x/5a5b5d48d1/240201_ir_fy23_en.pdf
2. https://ir.genmab.com/news-releases/news-release-details/genmab-publishes-2023-annual-report
3. https://www.sobi.com/sites/default/files/pr/202402073989-1.pdf
4. https://ir.kyowakirin.com/en/library/earnings/earnings0/main/011117/teaserItems1/00/linkList/04/link/transcript_2023_q4_en.pdf